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uncertainty, the Swiss Working Group for interstitial and rare 
lung diseases of the Swiss Respiratory Society provides a po-
sition paper on the diagnosis and treatment of IPF. 
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 Introduction 
 Idiopathic pulmonary fibrosis (IPF) is a severe pro-
gressive lung disease. There is no available treatment to 
reverse the fibrotic process  [1, 2] . With recent publica-
tions of positive phase III studies and approval of novel 
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 Abstract 
 Idiopathic pulmonary fibrosis (IPF) is a severe progressive 
and irreversible lung disease. Novel antifibrotic drugs that 
slow disease progression are now available. However, many 
issues regarding patient management remain unanswered, 
such as the choice between available drugs, their use in par-
ticular subgroups and clinical situations, time of treatment 
onset, termination, combination or switch, or nonpharma-
cologic management. To guide Swiss respiratory physicians 
in this evolving field still characterized by numerous areas of 
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antifibrotic drugs to slow lung function decline, several 
national and international respiratory societies have de-
cided to update existing guidelines or endorse new inter-
national guidelines  [3–5] . The antifibrotic drugs pirfeni-
done and nintedanib are now recommended for patients 
with IPF according to the latest ATS/ERS/JRS/ALAT 
guidelines  [2] . Yet, many questions regarding the man-
agement of IPF patients remain the subject of debate  [2] , 
for instance, when to start and when to stop treatment.
 Now that nintedanib and pirfenidone have been ap-
proved by the Swiss health authorities (SwissMedic) and 
they are available for prescription, the Swiss Working 
Group for interstitial and rare lung diseases of the Swiss 
Respiratory Society decided to formulate a position paper 
to guide physicians in Switzerland in the diagnosis and 
treatment of IPF. In addition, due to the different lan-
guages used in Switzerland, Swiss physicians often refer 
to guidelines in their mother tongue, which might lead to 
different treatment approaches in one country. Thus, 
German and French recommendations have been com-
pared with the current international guidelines to estab-
lish a national recommendation for Switzerland.
 Methodology 
 The recommendations in this position paper are based on the 
current international literature and opinion of the members of the 
Swiss Working Group for interstitial and rare lung diseases of the 
Swiss Respiratory Society (A.A., D.A., C.B.-A., A.B., P.-O.B., M.B., 
C.C., M.F.-C., K.H., R.L., R.K.-F., and T.G., hereafter called the 
“working group”).
 A core panel was constituted with all members of the working 
group. A review panel was constituted by adding selected experts 
to the core panel (C.B., L.P.N., and P.M.S.). As a first step, a list of 
questions to be addressed was established (M.F.-C., T.G., and R.L.) 
and was distributed for review. Using an electronic survey tool, we 
classified the relevance of each question as “very important,” “im-
portant,” “of limited interest,” or “unimportant,” rated between
1 = “fully disagree” and 9 = “fully agree.” Individual votes are rep-
resented in the percentage of votes for each grade. Questions con-
sidered by the majority as “very important” and “important” were 
reviewed, discussed, and reformulated if needed. A standardized 
wording was defined to express the strength of the recommenda-
tions: the terms “we recommend” or “should” were used to express 
a strong recommendation; the terms “we suggest” or “may” were 
used to express a weak recommendation; the terms “we do not rec-
ommend” or “should not” were used to express negative recom-
mendations.
 A first draft of possible responses was written (M.F.-C. and 
T.G.) and discussed in a face-to-face meeting. A second version 
was then established (M.F.-C., T.G., and R.L.) and redistributed for 
review. An iterative formal consensus technique (Delphi method) 
 [6] was then used to measure and improve consensus within the 
group, using an electronic survey tool. In each round, the members 
were asked to express their level of agreement with each recom-
mendation, using a 7-point Likert scale, and to provide comments 
as needed. For divergent points, the text was amended and recir-
culated for review. The Swiss recommendations of the working 
group are marked with gray shading in the text. The final level of 
agreement was expressed using the predefined wording ( Table 1 ). 
A summary of international, French, German, and Swiss recom-
mendations is given in  Table 2 for comparison.
 What Is IPF? 
 Clinical Presentation and Pathophysiology
of the Disease 
 IPF is a fibrosing process of the lung parenchyma usu-
ally resulting in a restrictive pattern on pulmonary func-
tional testing and impaired gas exchange, eventually lead-
ing to respiratory failure. Patients usually present with 
unspecific respiratory symptoms such as dyspnea on ex-
ertion and dry cough  [1] . The pathophysiology of IPF has 
been extensively investigated. The disease is now consid-
ered to be due to repeated microinjuries to the alveolar 
epithelium caused by unknown agents and an impaired 
wound healing response, which leads to impairment of 
the lung’s physiology  [7] .
 Research efforts at the cellular and molecular levels 
have shown that multiple cytokines and mediators are 
 Table 1.  Interpretation of the consensus level [6]
Perfect 
consensus
All respondents agree on an answer
Very good 
consensus
The median and middle 50% (interquartile 
range) of the respondents are found at 1 interval 
(e.g., the median and interquartile range are 
both at 8) or 80% of the respondents are within 
1 interval of the median (e.g., the median is 8, 
80% of the respondents are between 7 and 9)
Good 
consensus
50% of the respondents are within 1 interval of 
the median (e.g., the median is 8, 50% of the 
respondents are between 7 and 9) or 80% of the 
respondents are within 2 intervals of the median 
(e.g., the median is 7, 80% of the respondents 
are between 5 and 9)
Some 
consensus
50% of the respondents are within 2 intervals of 
the median (e.g., the median is 7, 50% of the 
respondents are between 5 and 9) or 80% of the 
respondents are within 3 intervals of the median 
(e.g., the median is 6, 80% of the respondents 
are between 3 and 9)
No consensus All other responses
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 Table 2. Overview of international, French, German, and Swiss recommendations
Comparison of guidelines for idiopathic pulmonary fibrosis
ATS 2011 German 2013 French 2013 ATS 2015  Swiss 2017
Method grade grade recommendations grade reco mmendations
Assessment
Bronchoalveolar lavage cellular analysis 2 3 + na 4
Transbronchial biopsy 2 2 na 2
Serology (RF, anti-CCP, ANA) 3 3 + 4
MDD 4 4 + 4
Genetics – – + 2
Site of biopsy na defined by MDD, 
no area with exclusive 
honeycombing
na defined by MDD, 
no area with 
exclusive 
honeycombing
Lung functional tests na na FVC, DLCO, 
blood gas, 
6-MWT, Bioxx
3
Treatment and prevention
Acetylcysteine monotherapy 2 3 + 2 1
Ambrisentan na na – 1 na
Anticoagulation 2 1 – 1  
Azathioprine, acetylcysteine, prednisone 2 1 – 1 1
Bosentan 1 1 – 2  
Colchicine 1 1 – na  
Combined corticosteroids and immunomodulator therapy 1 1 na na
Corticosteroid monotherapy 1 1 – na
Corticosteroids for acute exacerbation 3 3 + na 3
Cyclosporine A 1 1 – na
Etanercept 1 1 – na
Imatinib no recommen-
dation
1 na 1
Interferon-γ 1b 1 1 – na
Low-dose corticosteroids for treatment-resistant cough na na + na na
Lung transplantation 4 4 + no rec. single
vs. bilat.
4
Macitentan na na – 2
Invasive mechanical ventilation 2 2 – na 2
Nintedanib na na na 3 3
Oxygen therapy in hypoxic patients 4 4 + na 4
Palliative care with opioid treatment should be 
considered
3 na na 4
Pirfenidone no recommen-
dation
3 + 3 3
Pulmonary rehabilitation 3 3 + na 4
Sildenafil no recommen-
dation
na na 2
Tobacco cessation na 3 na na
Treatment of asymptomatic reflux 3 no recom-
mendation
+ 3 2
Treatment of pulmonary hypertension 2 treatment trial if 
severe with mild 
fibrosis
only if severe no recommen-
dation
1
Vaccination against influenza and pneumococcus na 3 + na na
Follow-up
Control every 3 – 6 months 3 +
 4, strong recommendation for; 3, weak recommendation for; 2, weak recommendation against; 1, strong recommendation against; +, recommendation 
for without weak or strong; –, recommendation against without weak or strong; “no recommendation,” question has been addressed, but no recommenda-
tion has been formulated; na, not addressed. Transplantation: the Swiss recommendations are strong for considering transplantation. RF, rheumatoid factor; 
CPP, cyclic citrullinated peptide; ANA, anti-nuclear antibodies; MDD, multidisciplinary discussion; FVC, forced vital capacity; DLCO, diffusing capacity of 
the lung for carbon monoxide; 6-MWT, 6-min walk test.
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implicated in IPF pathogenesis, and transforming 
growth factor (TGF)-β was identified as a key player  [8] . 
TGF-β, PDGF (platelet-derived growth factor), FGF
(fibroblast growth factor), and VEGF (vascular endothe-
lial growth factor) are profibrotic cytokines which
are targets of current therapeutic approaches  [8] . Excessive
production of these and other cytokines leads to accu-
mulation of differentiated fibroblasts, so-called myofi-
broblasts, in the alveolar interstitium. Myofibroblasts 
produce and modify the extracellular matrix (e.g., col-
lagen), which alters the normal lung architecture and 
impairs gas exchange. 
 The histopathological features of IPF include fibro-
blast foci, which represent subepithelial accumulations of 
myofibroblasts in fibrotic areas with adjacent dense col-
lagen deposits, and spatial and temporal heterogeneity of 
fibrotic changes. These changes constitute the so-called 
usual interstitial pneumonia (UIP) pattern. The radiolog-
ical UIP pattern can be identified by high-resolution 
computed tomography (HRCT) if characteristic imaging 
features are present, and some correlations between his-
topathological changes and radiological features have 
been made previously (see below and  Table  3 )  [1, 9] . 
While an IPF diagnosis requires a radiological and histo-
logical UIP pattern (if histology has been performed), the 
presence of a UIP pattern does not necessarily implicate 
IPF, since it may occur in other contexts such as rheuma-
toid arthritis  [10] , chronic hypersensitivity pneumonitis 
 [11] , or connective tissue disease  [12] , which are impor-
tant differential diagnoses to exclude.
 Many factors have been found to increase the risk – or 
to contribute to the occurrence – of IPF, including old 
age  [1] , male gender  [13] , smoking  [14] , occupational
exposures, gastroesophageal reflux  [15–17] , and viral or 
bacterial infections  [18] . Genetic mutations (e.g., SPC, 
SPA, and telomerase genes) and single nucleotide poly-
morphisms (e.g., MUC5B) are increasingly identified in 
patients with IPF  [19] and strongly suggest that a genetic 
susceptibility plays a role in disease development  [19, 
20] .
 The prevalence of IPF is described as increasing in 
some populations  [21] . Data about the incidence and 
prevalence of pulmonary fibrosis vary due to changing 
case definitions in different countries  [22] . An overview 
on interstitial lung disease (ILD) prevalence or incidence 
rates in Europe, including data about IPF, was given in a 
paper describing the epidemiology of different ILDs in 
Greece  [23] . In Switzerland, there might be 100–5,000 
IPF patients (considering previously published data), 
with an incidence of 18–1,424 new patients per year na-
tionwide  [8] . However, the true incidence and prevalence 
as well as the genetic characteristics of IPF in Switzerland 
are currently unknown.
 Course of the Disease 
 Although new treatment options are now available, 
IPF remains a severe and life-threatening disease with a 
median survival of about 3 years  [1, 24] . The disease 
course can, however, differ considerably between indi-
vidual patients. While some remain almost stable for 
years, others may progress rapidly or experience episodes 
of acute worsening or exacerbation. Acute exacerbation 
of IPF (AE-IPF) is an acute, clinically significant respira-
tory deterioration characterized by evidence of new, 
widespread alveolar abnormalities that typically occur 
within less than 1 month  [25] . It is considered to be an 
independent acceleration of the disease process or re-
sponse to occult external events  [25, 26] . The annual in-
 Table 3. Radiological criteria for UIP [1]
UIP (all 4) Possible UIP (all 3) Inconsistent with UIP (any of 7)
Subpleural, basal predominance
Reticular abnormality
Honeycombing with or without traction 
bronchiectasis
Absence of features listed as inconsistent 
with UIP
Subpleural, basal predominance
Reticular abnormality
Absence of features listed as inconsistent 
with UIP
Upper or mid-lung predominance
Peribronchovascular predominance
Extensive ground-glass abnormality 
(extent > reticular abnormality)
Profuse micronodules
Discrete cysts
Diffuse mosaic attenuation/air trapping
Consolidation in bronchopulmonary 
segment
UIP, usual interstitial pneumonia.
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cidence of AE-IPF has been estimated around 5% in pla-
cebo arms of recent randomized controlled trials, with a 
median survival of less than 3 months  [27] . CT scanning 
during AE-IPF typically shows new ground-glass opaci-
ties superimposed on preexisting chronic fibrotic chang-
es  [26] . If biopsies are available, diffuse alveolar damage 
is usually present on the underlying UIP  [26] . The defini-
tion of AE-IPF has recently been updated  [25] .
 Exclusion of alternative causes – specifically heart fail-
ure as well as pulmonary embolism, pleural effusion, and 
pneumothorax – is crucial, as these causes affect the treat-
ment approach and prognosis  [25, 26] . While exclusion 
of infection by bronchoalveolar lavage (BAL) or endotra-
cheal aspirate has previously been required, it is no longer 
mandatory for the redefined term of “acute exacerbation” 
 [25, 27] . Nevertheless, infections need to be searched for, 
as they inform treatment decisions.
 No reliable marker for predicting the disease course in 
IPF is available today, although MUC5B polymorphisms 
have been associated with better survival  [28] , and a vari-
ant of TOLLIP was related to higher mortality  [29] . To-
day, only MUC5B polymorphisms and MMP7 are con-
sidered potential biomarkers of IPF disease course, even 
if no biomarker is used in clinical practice yet.  [30] More 
commonly used in clinical practice are clinical and phys-
iological variables (gender, age, forced vital capacity 
[FVC], and diffusing capacity of the lung for carbon mon-
oxide [D LCO ]) to predict mortality among patients with 
IPF, using various clinical scores such as the GAP index 
 [31] .
 Diagnosis of IPF 
 Current international guidelines require the exclusion 
of other known causes of ILD, the presence of a UIP pat-
tern on HRCT if no surgical biopsy is obtained, or spe-
cific combinations of HRCT and surgical lung biopsy 
(SLB) if a biopsy is performed  [1] . Most challenging is the 
exclusion of secondary causes of fibrosis. The initial step 
is thus a thorough patient history to exclude any environ-
mental, occupational, or drug exposure to agents with 
profibrotic side effects. The patient history can point to 
connective tissue disease. The family history might reveal 
hereditary forms of pulmonary fibrosis, which is found in 
about 5% of cases  [1] . History-taking should also include 
a search for possible triggering factors (e.g., gastroesoph-
ageal reflux) and comorbidities like obstructive sleep ap-
nea or signs of coronary heart disease  [1] .
 A clinical examination might reveal signs of chronic 
hypoxemia with finger clubbing and, eventually, cyano-
sis in advanced situations. Pulmonary auscultation usu-
ally reveals typical bibasilar Velcro crackles. Pulmonary 
functional tests may typically show a restrictive ventila-
tory defect with a reduced diffusion capacity and, possi-
bly, hypoxia. If performed, exercise testing uncovers gas 
exchange impairment by desaturation during exercise 
 [1] .
 According to international guidelines, a UIP needs to 
be present on HRCT for a diagnosis, which includes a 
subpleural and basal predominance of lesions, reticular 
abnormalities, honeycombing with or without traction 
a b
 Fig. 1. Typical high-resolution computed tomography images of an idiopathic pulmonary fibrosis patient ( a ,  b ) 
with a basal gradient ( b ), honeycombing, and traction bronchiectasis in the absence of a predominance of ground 
glass. 
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bronchiectasis, and an absence of features inconsistent 
with a UIP pattern ( Table 1 ;  Fig. 1 ). Identifiable causes 
need to be excluded. If radiological imaging is inconsis-
tent with a UIP, biopsy is required to confirm the UIP 
pattern ( Fig. 2 ) and a diagnosis should be established after 
multidisciplinary discussion (MDD)  [1] . A modified di-
agnostic algorithm from the international guidelines  [1] 
has previously been proposed  [8] . Detailed descriptions 
of imaging ( Table 1 ) and histopathological UIP patterns 
are also summarized in the international ATS/ERS guide-
lines  [1] .
 Which Physiological Tests Should Be Performed at the 
Time of Diagnosis (Evaluation of Prognosis) and for 
Follow-Up in Patients with Suspected IPF? 
 Although physiological testing is not formally required 
for an initial diagnosis of IPF according to the ATS/ERS/
JRS/ALAT, some parameters, such as a D LCO <40%, are 
predictive of increased mortality, and changes in FVC 
signal disease progression  [1] . In the German guidelines 
for diagnosis and treatment of IPF, lung functional chang-
es with a decline in FVC  ≥ 10% or a decline in FVC <10% 
combined with a decrease in D LCO , deteriorated arterial 
blood gas analysis or 6-min walk test (6-MWT) results, 
and clinical symptoms (dyspnea and cough) should be 
used to determine disease progression and prognosis  [3] . 
In addition, the German consensus conference considers 
changes in FVC or inspiratory vital capacity as equal pa-
rameters  [3] . The current French recommendation sug-
gest a combination of symptoms (severity of dyspnea), 
lung functional tests (FVC and D LCO ), the 6-MWT, the 
extent of honeycombing on HRCT, pulmonary hyperten-
sion (PH) on echocardiography, and using a score to as-
sess prognosis  [4] .
 In addition to D LCO and spirometry (FVC) to assess disease 
prognosis and progression in accordance with international rec-
ommendations, we suggest performing body plethysmography 
in search of a restrictive ventilatory disorder. The 6-MWT (in 
search of exercise-induced oxygen desaturation) should be per-
formed routinely at the time of diagnosis in patients with suspi-
cion of IPF as a reference value to evaluate disease progression. 
Arterial blood gas analysis should not be performed routinely, 
unless long-term oxygen therapy is considered. Spiroergometry 
may be performed if driven by a specific clinical question.  (Very 
good consensus) (1–6 = 0 votes, 7 = 10% of votes, 8 = 10% of 
votes, 9 = 80% of votes) 
 Which Laboratory Tests Should Be Performed at the 
Time of Diagnosis of Suspected IPF? 
 Serological analyses should be performed according to 
international guidelines  [1] to exclude secondary causes, 
specifically since some rheumatologic diseases may man-
ifest as lung fibrosis before systemic symptoms become 
apparent  [1, 3] . International recommendations accord-
ing to the ATS/ERS/JRS/ALAT include systematic sero-
logical testing even in the absence of symptoms of con-
nective tissue disease, such as rheumatoid factor, anti-cy-
clic citrullinated peptide, and anti-nuclear antibody titer 
and pattern. Further serological testing (anti-Jo-1, -SSA, 
-SSB, and -Scl-70) is only considered in selected cases be-
cause of an unclear benefit  [1] . The German recommen-
dation adopts this proposal  [3] . In order to exclude con-
nective tissue disease-associated ILDs, the French recom-
mendations suggest assessing (1) differential blood cell 
counts, as well as C-reactive protein, serum creatinine, 
transaminase, γ-glutamyltransferase, and alkaline phos-
phatase; (2) anti-nuclear antibodies, anti-citrullinated cy-
clic peptide antibodies, and rheumatoid factor; and (3), 
depending on the clinical picture or if anti-nuclear anti-
a b
 Fig. 2.  a Typical histopathological UIP (usual interstitial pneumonia) pattern with a heterogeneous distribution 
and fibroblast foci.  b Typical fibroblast foci with myofibroblast accumulation. 
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bodies are present, antibodies specific to the Sjögren syn-
drome (anti-SSA and anti-SSB), systemic sclerosis anti-
bodies (anti-centromere, anti-topoisomerase-1, and anti-
U3RNP antibodies), anti-synthetase antibodies, anti-
thyroid antibodies, creatinine phosphokinase, and serum 
electrophoresis  [4] . A recent review suggests anti-nuclear 
antibodies, Jo-1, SSA, SSB, rheumatoid factor, anti-CCP, 
and anti-neutrophil cytoplasmic antibodies as screening 
markers for all patients with unclear ILD  [32] .
 We recommend routine blood testing including erythrocyte 
sedimentation rate, differential blood cell count, C-reactive pro-
tein, and renal (blood, urine dip stick) and liver function, as well 
as serological markers for systemic autoimmune diseases (anti-
nuclear antibodies, rheumatoid factor, and anti-cyclic citrullinat-
ed peptide). These tests may be repeated during the disease 
course if new clinical aspects appear. We suggest performing ex-
panded serological testing when an autoimmune disease is sus-
pected based on a thorough patient history and clinical examina-
tion. This may include markers for mixed connective tissue dis-
ease (anti-U1 ribonucleoprotein antibodies), Sjögren syndrome 
(anti-SSA and anti-SSB antibodies), and systemic lupus erythe-
matosus (Sm, dsDNA), as well as specific antibodies for idio-
pathic inflammatory myopathies (anti-Jo-1, anti-PL7, and anti-
PL12), systemic sclerosis (anti-centromere, anti-topoisomer-
ase-1, and anti-U3RNP), and vasculitis (anti-neutrophil 
cytoplasmic autoantibodies). Serological markers for inflamma-
tory myopathies (e.g., anti-Jo-1 antibodies) may also be deter-
mined in asymptomatic patients, since ILD can occur with or 
without preceding myopathy.  (Very good consensus) (1–6 =
0 votes, 7 = 10% of votes, 8 = 30% of votes, 9 = 60% of votes) 
 Should Patients with a UIP Pattern and Clinical or 
Serological Autoimmune Features Who Do Not Meet 
the Definite Diagnostic Criteria for a Connective 
Tissue Disease Be Considered as Having IPF? 
 Some patients present with clinical features suggesting 
an underlying autoimmune process, but they do not meet 
the established criteria for a connective tissue disease; this 
has been called “interstitial pneumonia with autoimmune 
features” (IPAF). Evidence of treatment for this newly
described population is missing  [33] .
 We recommend that the diagnosis and treatment decisions 
for interstitial pneumonia with autoimmune features be left with 
experienced MDD groups.  (Very good consensus) (1–7 =
0 votes  8 = 10% of votes, 9 = 90% of votes) 
 Should Bronchoscopy and BAL Be Performed if IPF Is 
Suspected? 
 Lymphocytosis  ≤ 15% or eosinophilia  ≤ 1% in BAL flu-
id are considered normal. Alterations in cytopathological 
cell distribution in BAL fluid should initiate a search for 
a diagnosis other than IPF  [34, 35] . In the guidelines from 
the ATS/ERS/JRS/ALAT, BAL is not routinely recom-
mended  [1] . In contrast, routine BAL to investigate ILD 
is recommended by the German IPF guidelines  [3] . The 
French recommendation also includes BAL in suspected 
IPF, especially if HRCT does not show a definite UIP pat-
tern  [4] . Controlled studies are needed to establish the 
true benefit of BAL for ruling out differential diagnoses.
 We recommend performing BAL to search for other causes 
of a fibrotic disease, especially chronic hypersensitivity pneumo-
nitis and fibrotic nonspecific interstitial pneumonia, in patients 
with suspected IPF if the risk of performing BAL is considered 
inferior to the possible benefit to diagnostic accuracy. If chest 
imaging does not show a definite UIP pattern, BAL and a biopsy-
confirmed UIP diagnosis should be aimed at. Not performing 
BAL is justified, specifically if the individual respiratory situation 
considerably increases the risk of the procedure.  (Very good con-
sensus) (1–6 = 0 votes, 7 = 10% of votes, 8 = 0 votes, 9 = 90% 
of votes) 
 If Indicated, Which Type of Histological Biopsy Should 
Be Performed: Transbronchial Biopsy, Cryobiopsy, or 
SLB? 
 International guidelines discourage the use of trans-
bronchial biopsy in IPF patients, with a weak recommen-
dation due to low-quality evidence  [1, 3] . Meanwhile, 
new techniques have been developed. Cryobiopsy has 
shown good diagnostic yield in initial studies and can be 
performed safely in comparison to SLB  [36] . Cryobiopsy 
has increased diagnostic confidence in multidisciplinary 
diagnosis of IPF  [37] . Nevertheless, its diagnostic accu-
racy has not been properly evaluated in direct compari-
son to SLB  [38] . Cryobiopsy might be an additional diag-
nostic option in the future if performed in experienced 
centers; however, is not routinely used in Switzerland at 
the present time. In unclear cases, surgical biopsy (video-
assisted thoracoscopy) may still be needed to achieve a 
diagnosis. Possible risks of performing video-assisted 
thoracoscopy and cryobiopsy need to be considered.
 We do not recommend transbronchial biopsy for suspected 
IPF. We recommend performing video-assisted thoracoscopic 
SLB if ILD remains unclassifiable or possible UIP is diagnosed 
after an MDD and if the patient-specific risk of performing SLB 
is considered inferior to its benefit to diagnostic accuracy. SLB 
should be performed only if the result is expected to strongly in-
fluence therapeutic decisions, especially if the choice between an-
tifibrotic and anti-inflammatory/immunosuppressive treatment 
is difficult in idiopathic interstitial pneumonia with an unclear 
pattern. SLB should not be performed if it will not result in any 
treatment decision. SLB should not be performed in patients with 
severely impaired lung functional testing results, significant co-
morbidities, or advanced biological age. The sites of lung biopsy 
should be chosen in an MDD with a chest physician, radiologist, 
and thoracic surgeon. Whenever possible, samples should be tak-
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en from at least 2 lobes. The tips of the middle lobe and of the 
lingula should be avoided, as well as areas with exclusive honey-
combing. Cryobiopsy may be considered as an alternative ap-
proach in experienced centers if there are no contraindications. 
Not performing biopsy may be an acceptable option for individ-
ual patients, specifically if the radiological signs favor possible 
UIP.  (Very good consensus) (1–5 = 0 votes, 6 = 10% of votes, 
7–8 = 0 votes, 9 = 90% of votes) 
 What Is the Role of MDD? 
 MDD is considered the gold standard for IPF diagno-
sis and should involve at least a pulmonologist, a radiolo-
gist, and a pathologist with expertise in ILD  [1, 3, 39] . 
MDD has been shown to increase diagnostic confidence 
regarding IPF in this setting  [40] . With IPF being a rare 
disease, patients should be referred to expert centers for 
diagnosis, and their cases should be discussed in an expe-
rienced ILD MDD to achieve the highest possible diag-
nostic accuracy – even more so because interobserver 
agreement between radiologists regarding UIP on HRCT 
is only moderate independently of their respective clini-
cal experience  [41] .
 We recommend MDD with at least a pulmonologist, a radi-
ologist, and a pathologist (all with ILD expertise) at experienced 
centers for all IPF diagnoses, both before and after biopsy. MDD 
before surgical biopsy should suggest the site of biopsy to im-
prove diagnostic outcome. Treatment suggestions should be for-
mulated in MDD whenever possible.  (Perfect consensus) (1–8 = 
0 votes, 9 = 100% of votes) 
 Should Genetic Mutations Be Searched for once the 
Diagnosis Is Established? 
 The 2011 international guidelines did not recommend 
genetic screening for IPF patients  [1] . Meanwhile, several 
associations between IPF and genetic mutations or poly-
morphisms have been identified. Some genetic variants are 
associated with increased or reduced survival and may pre-
dict disease outcome  [28, 29] . Knowledge of these genetic 
determinants might affect the timing of referral to lung 
transplantation centers. Genetic counseling can also help 
to identify familiar forms of fibrosis. In addition, some 
polymorphisms may influence the response to specific 
treatments, such as TOLLIP mutations for N-acetylcyste-
ine (NAC) treatment  [42] . Although the German guide-
lines did not recommend routine screening yet, they un-
derlined the current change of knowledge in this field  [3] .
 We recommend genetic testing for gene mutations if familial 
fibrosis is suspected or IPF occurs at a younger age (<50 years). 
At the present time, we do not suggest searching for genetic poly-
morphisms (MUC5B, etc.) in the routine clinical setting for all 
IPF patients.  (Very good consensus) (1–4 = 0 votes, 5 = 10% of 
votes, 6–7 = 0 votes, 8 = 10% of votes, 9 = 70% of votes) 
 Comorbidities 
 Comorbidities and complications are common in IPF 
patients  [43] . These patients have an increased risk of 
lung cancer  [43] . Since IPF itself reduces life expectancy, 
it is unclear today if screening methods recommended for 
risk populations are of any benefit to these patients  [44] . 
PH  [45] , obstructive sleep apnea syndrome  [46] , gastro-
esophageal reflux  [15] , and coronary heart disease are 
more common in IPF patients than in the general popula-
tion  [1] . Examinations to diagnose or exclude comorbid-
ities depend on symptoms and clinical presentation.
 Current Recommendations for Treatment 
 The approach to treatment for IPF has considerably 
changed over the past few years. Many previously used 
treatments have been shown to be ineffective and are 
therefore no longer recommended. Specifically, immu-
nosuppressive therapies – e.g., triple therapy with pred-
nisone, azathioprine, and NAC – did not show any ben-
efit and were even considered harmful  [47] . Other inef-
fective treatments are listed in the current international 
guidelines  [1, 2] .
 A novel category of treatment has emerged out of re-
cent clinical trials. Antifibrotic drugs include currently 2 
substances, pirfenidone and nintedanib, which mainly 
target fibrosis progression. Pirfenidone is an antifibrotic 
agent that interferes with the TGF-β pathway, although 
its exact mode of action remains unclear. In vitro studies 
have shown that pirfenidone inhibits fibroblast prolifera-
tion and differentiation into myofibroblasts through in-
hibition of TGF-β  [48] . In 2 out of 3 placebo-controlled 
clinical randomized phase III trials (CAPACITY: PIPF-
004, PIPF-006, and ASCEND), pirfenidone significantly 
slowed the decline in FVC  [49, 50] . The decline in FVC 
was reduced by 193 mL in pirfenidone-treated patients 
compared to placebo-treated ones after 52 weeks in the 
ASCEND trial including 555 IPF patients in total  [50] . 
The diagnosis of IPF was confirmed if the diagnostic cri-
teria according to the current ATS/ERS guidelines were 
met (i.e., exclusion of an alternative diagnosis of ILD with 
a definite UIP pattern on HRCT or possible UIP with sur-
gical biopsy showing a UIP pattern)  [1] . If radiological 
imaging showed greater emphysematous changes than
fibrotic changes, patients were excluded  [50] . The
ASCEND trial showed prolonged progression-free sur-
vival among pirfenidone-treated patients after 52 weeks 
 [50] . A pooled data analysis of the CAPACITY and AS-
CEND trials suggests a positive effect on mortality ( p = 
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0.011)  [50] . Reported side effects are mainly gastrointes-
tinal and skin-related events during clinical trials and 
long-term observations  [51] . It is recommended that pir-
fenidone be taken with meals to reduce gastrointestinal 
side effects. Spacing the ingestion of the 3 tablets and pro-
kinetic medication as well as proton pump inhibitors can 
reduce side effects  [52] . Because of increased photosensi-
tivity, patients should be advised to avoid direct exposure 
to sunlight, to use sunscreens, and to wear protective 
clothing outside  [52] . Pirfenidone should not be used 
with end-stage renal disease and severe hepatic dysfunc-
tion (Child-Pugh class C). Liver function needs to be 
monitored prior to treatment, as well as regularly during 
treatment (initially every month for 6 months, then every 
3 months if stable)  [52] . The concomitant use of fluvox-
amine should be avoided because of decreased drug clear-
ance through inhibition of CYP1A2. Ciprofloxacin re-
duces pirfenidone clearance by the same mechanism. 
Omeprazole might also influence the pharmacokinetics 
of pirfenidone  [53] .
 Pirfenidone has been recommended for patients with 
IPF (weak recommendation, moderate evidence) by the 
German  [3] as well as international guidelines (condi-
tional or weak recommendation for use, moderate confi-
dence in estimates of effect)  [2] . The French guidelines 
recommend its use in mild-to-moderate IPF  [4] .
 Nintedanib is a tyrosine kinase inhibitor targeting 
PDGF, FGF, and VEGF receptors. The antifibrotic mech-
anisms of tyrosine kinase inhibition by nintedanib have 
been extensively studied  [54] , and inhibitory effects on 
proliferation and extracellular matrix production have 
been shown in lung fibroblasts derived from IPF patients 
 [55] . In clinical trials, 2 concurrent phase III studies (IN-
PULSIS-1 and -2) were conducted with a centrally re-
viewed diagnosis of IPF  [56] . IPF was confirmed if spe-
cific criteria were met  [56] . Both studies showed a sig-
nificant reduction of the decline in FVC (a difference of 
124 and 94 mL, respectively, between treated patients and 
placebo controls,  p < 0.001) in patients with the following 
inclusion criteria: FVC >50%; FEV 1 (forced expiratory 
volume in 1 s)/FVC >0.7; and D LCO 30–79%. In a pre-
specified, pooled analysis of a key secondary endpoint, 
the time to first acute exacerbation was reduced  [56] . 
However, in individual studies, only INPULSIS-2 showed 
a significant benefit on time to first exacerbation. Anoth-
er secondary endpoint (change in total score on the St. 
George Respiratory Questionnaire [SGRQ]) did not re-
veal any statistically significant difference in pooled anal-
yses  [56] . No beneficial effect on survival has been re-
ported, including in pooled analyses, although a trend
towards reduced all-cause mortality and respiratory
mortality was observed, with reduced on-treatment mor-
tality and time to first investigator-reported acute exacer-
bation when phase II and phase III studies were com-
bined  [57] . The main side effects of nintedanib reported 
were diarrhea, nausea, abdominal pain, and vomiting 
 [56] . Although diarrhea is a common side effect, it is mild 
to moderate in most cases and can be treated with anti-
motility drugs  [52] . Liver function needs to be checked 
prior to treatment and every month for 3 months, then 
every 3 months  [52] . Nintedanib should not be used in 
case of liver disease (Child-Pugh classes B and C)  [52] . Its 
safety and efficacy in severe renal failure have not been 
evaluated, and treatment is thus not recommended  [52] . 
Treatment should be conducted with care if known car-
diovascular diseases or significant risk factors are present 
and the risk of bleeding is increased  [52] , although no 
clear contraindication has been formulated.
 Recently, 2 network meta-analyses investigated stud-
ies on IPF and found consistently beneficial results for 
both pirfenidone and nintedanib in comparison to other 
treatments. No superiority of either drug could be dem-
onstrated. The conclusion about mortality was divergent 
and needs to be considered carefully  [58, 59] .
 Similar to pirfenidone, nintedanib is now recom-
mended by international guidelines (conditional or weak 
recommendation for use, moderate confidence in esti-
mates of effects)  [2] . Study data were not available yet 
when the German and French recommendations were 
published. 
 We suggest treatment with pirfenidone or nintedanib for pa-
tients with IPF. In the absence of direct comparisons, none of the 
2 drugs can currently be considered superior to the other. The 
effect on decline in FVC appears of a similar magnitude with ei-
ther of the 2 drugs. At the present time, the choice between these 
2 drugs should therefore mainly rely on preferences regarding the 
side effect profile, contraindications to treatment, and comor-
bidities.  (Very good consensus) (1–6 = 0 votes, 7 = 10% of 
votes, 8 = 10% of votes, 9 = 70% of votes) 
 When Should Antifibrotic Treatment Be Started? 
 Randomized trials of pirfenidone (ASCEND) and 
nintedanib (INPULSIS) on IPF included patients with 
moderately severe disease (FVC 50–90 and >50%, D LCO 
30–90 and 30–79%, and FEV 1 /FVC >80 and >70%, re-
spectively; 6-MWT distance >150 m in ASCEND only) 
 [50, 56] . However, the benefit from therapy might not be 
related to disease stage. In patients treated with ninte-
danib, whether the initial FVC was <70 or >70% did not 
significantly influence the drug’s effect on decline in FVC, 
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SGRQ score, or time to first exacerbation, although in 
patients with a lower FVC, more acute exacerbations and 
greater deterioration were reported in the placebo-treat-
ed group  [60] . In real-life observations, pirfenidone 
showed efficacy in reducing the decline in FVC in more 
advanced disease  [61] . Rapid lung functional decline or 
exacerbation can occur at any stage. Thus, long observa-
tional periods without treatment may not be useful. A 
patient’s preferences regarding treatment need to be in-
cluded in the decision-making process about initiation of 
therapy. Patients should be clearly informed about the 
expected disease course and the risks and benefits of ther-
apy – especially the fact that treatment will not improve 
lung function but only slow down disease progression, 
and that they likely will not feel any improvement of 
symptoms or quality of life. On the other hand, early 
treatment may preserve lung function and avoid addi-
tional respiratory symptoms  [53] .
 We suggest that antifibrotic treatment be proposed upon di-
agnosis of IPF, especially in patients with documented disease 
progression as shown by worsening of symptoms, lung function-
al impairment, or chest imaging. An observational period with-
out antifibrotic treatment may be appropriate in selected patients 
with mild and stable disease and comorbidities. If no treatment 
is started, patients should be followed up every 3–6 months and 
be reevaluated for treatment initiation. The choice of the initial 
drug should depend on a patient’s preferences, comorbidities, 
and concomitant treatments.  (Very good consensus) (1–7 =
0 votes, 8 = 10% of votes, 9 = 90% of votes) 
 Should We Treat Patients with Probable or Possible 
IPF, and with Fibrotic Lung Disease other than IPF? 
 Patients with possible IPF were included in the IN-
PULSIS studies with nintedanib. A prespecified subgroup 
analysis (sex, age, race, baseline FVC, systemic corticoste-
roid use, etc.) showed consistent effects of nintedanib on 
possible UIP compared to definite UIP  [62] . The diagno-
sis of probable and possible IPF should involve MDD.
 Lung fibrosis other than IPF might have overlapping 
pathogenic disease mechanisms, although there are clear 
differences in disease course and prognosis in patients 
with lung fibrosis other than IPF. In contrast to IPF, fi-
brotic ILD occurring in connective tissue disease patients 
may benefit from immunosuppressive therapy. Although 
the studies are ongoing, the effect of pirfenidone or nin-
tedanib on ILD associated with connective tissue disease 
is currently unknown  [63] .
 We suggest that only patients with definite IPF be treated with 
antifibrotic agents. Treatment of probable and possible IPF 
should be discussed in MDD. We suggest not using antifibrotic 
drugs for diseases other than IPF until evidence on drug benefits 
is available.  (Very good consensus) (1–2 = 0 votes, 3 = 10% of 
votes, 4 = 0 votes, 5 = 10% of votes, 6–7 = 0 votes, 8 = 20% of 
votes, 9 = 60% of votes) 
 Should Patients with Severely Impaired Lung Function 
Be Treated with Pirfenidone or Nintedanib? 
 New data are emerging that support the use of antifi-
brotic drugs outside the lung functional values that were 
used for inclusion in studies on pirfenidone and ninte-
danib. Pirfenidone seems to be more effective in rapidly 
progressive IPF  [64] . For nintedanib, FVC at baseline 
seems not to influence treatment effects  [65] .
 We recommend that treatment with antifibrotic medication 
should also be offered to patients with severe forms of IPF if pal-
liation is not yet considered.  (Very good consensus) (1–6 =
0 votes, 7 = 10% of votes, 8 = 0 votes, 9 = 90% of votes) 
 Should We Treat Patients with Combined Pulmonary 
Fibrosis and Emphysema Syndrome? 
 Combined pulmonary fibrosis and emphysema 
(CPFE) is a clinicoradiological syndrome characterized 
by the simultaneous occurrence of both emphysema 
(usually of the paraseptal type with predominance in the 
upper lung zones) and ILD (usually in the lower lung 
zones) in variable proportions on chest CT  [66–68] . 
These patients have a particular lung functional profile 
with near-normal lung volumes and severely reduced 
D LCO , resulting on the one hand from opposed effects of 
fibrosis and emphysema on lung mechanics, and on the 
other hand from additive effects on gas exchange. PH is 
a common feature of CPFE and is associated with poor 
prognosis  [69] . The decline in lung volume over time was 
reported to be milder in CPFE than in IPF, but survival 
appears similarly poor  [70, 71] . It is unclear whether 
CPFE is a single disease or the simultaneous occurrence 
of 2 disorders sharing 1 or more risk factors such as 
smoking. Emphysema in IPF patients is associated with 
worse prognosis  [72] . The fibrotic component of CPFE 
could correspond to UIP on imaging or histologically. 
However, other histological patterns have been reported, 
such as nonspecific interstitial pneumonia  [73] . Patients 
with emphysema in addition to IPF have been excluded 
from the pirfenidone trials, but not from the nintedanib 
trial.
 We recommend treating the fibrosis component of CPFE 
with pirfenidone or nintedanib if this component meets the di-
agnostic criteria for IPF and the fibrotic disease is predominant 
over emphysematous areas.  (Very good consensus) (1–6 =
0 votes, 7 = 10% of votes, 8 = 10% of votes, 9 = 80% of votes) 
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 When Should Antifibrotic Treatment Be Stopped or 
Switched? 
 Clinical trials of IPF therapy with pirfenidone followed 
subjects up to 72 months  [49] . Pirfenidone has been well 
tolerated and documented for nearly 10 years of treat-
ment  [51, 74] . Sustained differences in lung functional 
decline were observed between intervention and placebo 
groups in those trials over time. In contrast, cessation of 
antifibrotic therapy has not specifically been studied. Giv-
en that pathophysiological IPF mechanisms evolve over 
months or years and are slowed but neither stopped nor 
reversed by either nintedanib or pirfenidone, specific 
therapy should generally not be stopped. One recent 
study showed that in patients with IPF progression de-
spite pirfenidone therapy, treatment maintenance was as-
sociated with better outcome when compared to patients 
progressing under placebo  [75] . In IPF patients with sig-
nificant side effects, stopping or reducing antifibrotic 
therapy may be necessary. It has also been reported that 
switching from one drug to another was safe  [76] .
 In IPF patients treated with antifibrotic drugs, disease pro-
gression should not be interpreted as treatment failure and lead 
to treatment withdrawal, provided that treatment tolerance is 
satisfactory. If intolerable side effects occur, a treatment switch 
might be considered.  (Very good consensus) (1–6 = 0 votes, 7 = 
10% of votes, 8 = 0 votes, 9 = 90% of votes) 
 Should Pirfenidone and Nintedanib Be Combined? 
 The safety and pharmacokinetics of the combination 
of pirfenidone and nintedanib have been studied. Ninte-
danib showed lower serum levels when added to pirfeni-
done in this study  [77] . Studies examining the efficacy of 
combination therapies have not been made until today.
 In the current absence of evidence regarding the benefit of 
combined therapy, we recommend that combining pirfenidone 
and nintedanib in IPF patients be avoided.  (Very good consen-
sus) (1–6 = 0 votes, 7 = 10% of votes, 8 = 0 votes, 9 = 90% of 
votes) 
 Should Patients Be Treated with NAC? 
 High-dose NAC treatment (600 mg 3×/day) had been 
considered standard therapy in addition to azathioprine 
and prednisone until the PANTHER trial showed in-
creased mortality and morbidity in its triple-therapy arm, 
which was therefore prematurely stopped  [47] . Adminis-
tration of high-dose NAC versus placebo did not show any 
benefit  [78] . A recent randomized controlled trial examin-
ing the effect of NAC or placebo on IPF patients treated 
with pirfenidone did not find any benefit from the addi-
tion of NAC  [79] . One study investigated the effects of 
NAC on death, transplantation, hospitalization, or decline 
of  ≥ 10% in FVC depending on different single nucleotide 
polymorphisms (SNPs) within TOLLIP or MUC5B. While 
one SNP within TOLLIP (rs3750920 TT genotype) signif-
icantly reduced these specific endpoints, another SNP 
(TOLLIP CC genotype) showed a trend towards harm 
 [42] . Thus, without systematic genotyping and additional 
studies, no therapeutic recommendation is possible.
 We do not recommend high-dose NAC treatment for IPF. 
 (Perfect consensus) (1–8 = 0 votes, 9 = 100% of votes) 
 Lung Transplantation 
 When Should IPF Patients Be Considered for 
Transplantation? 
 Lung transplantation is a well-accepted procedure for 
IPF and should be considered for patients without sig-
nificant comorbidities or obvious contraindications. Ab-
solute and relative contraindications to transplantation 
are similar to other indications for lung transplantation 
 [80] , but relative contraindications in particular vary 
among centers in Switzerland.
 The possibility of performing lung transplantation 
should be considered for all patients with IPF at the time 
of diagnosis, even if their lung function initially is well 
preserved, because of the poor prognosis of the disease 
 [80] . In general, IPF patients under 65 years of age with-
out significant comorbidities or contraindications should 
be referred early to a transplantation center for first as-
sessment and information about the benefits and risks of 
lung transplantation. Referral should specifically be con-
sidered when lung function is impaired and/or rapidly 
declining.
 Timely referral is crucial as the disease may progress 
rapidly. The time point at which to place a patient on the 
waiting list depends on the expected waiting time on the 
list, which is determined by the organ allocation system. 
In general, wait-listing is indicated when a patient’s lung 
function is severely impaired or rapidly deteriorating, 
manifesting itself in the following features (none of which 
should be used in isolation): (a) lung function declined 
(FVC by  ≥ 10% or D LCO by  ≥ 15% over 6 months); (b) O 2 
desaturation declined to <88%; (c) total walking distance 
declined to <250 m in the 6-MWT; (d) walking distance 
declined by >50 m over 6 months; (e) a diagnosis of PH 
is established; or (f) the patient needs hospitalization be-
cause of respiratory decline, pneumothorax, or acute ex-
acerbation  [80] . Once a patient is listed for lung trans-
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plantation, the transplantation center in close collabora-
tion with the treating pulmonologist should optimize 
every aspect of the candidate’s condition in order to 
maintain the patient suitable for transplantation. Patients 
should participate in a pulmonary rehabilitation pro-
gram.
 In case of acute exacerbations while on the waiting list, 
patients may be eligible for invasive ventilation or extra-
corporeal membrane oxygenation in case of single-organ 
failure, also as a “bridging measure” until transplantation. 
However, patients have to be selected very carefully in 
order to achieve acceptable posttransplantation out-
comes. Eligibility criteria for “bridging” strategies in this 
scenario differ between centers  [81] .
 The possibility of performing lung transplantation should be 
considered for all patients with IPF at the time of diagnosis, even 
if their lung function initially is well preserved. In particular, IPF 
patients under 65 years of age without significant comorbidities 
or contraindications and clinical and functional deterioration 
despite antifibrotic therapy should be referred early to a trans-
plantation center for initial assessment. Wait-listing is indicated 
when a patient’s lung function is severely impaired or rapidly 
deteriorating based on a combination of clinical and physiolog-
ical parameters following careful evaluation. Once a patient is 
listed for lung transplantation, the transplantation center and 
the treating pulmonologist should cooperate to maintain the pa-
tient suitable for transplantation.  (Good consensus) (1 = 20% of 
votes, 2 = 0 votes, 3 = 10% of votes, 4–7 = 0 votes, 8 = 10% of 
votes, 9 = 60% of votes) 
 Should Treatment Be Stopped if Patients Are Listed 
for Lung Transplantation? 
 Inhibition of the TGF-β pathway as well as inhibition 
of tyrosine kinases might theoretically interfere with the 
wound healing process. So far, no increased risks of op-
erative or postoperative complications have been report-
ed for IPF patients on either of these antifibrotic drugs.
 In general, stopping antifibrotic therapy is not recommended 
for patients on a waiting list for lung transplantation. However, 
a medical therapy should be performed after wait-listing in close 
collaboration between the transplantation center and the treating 
pulmonologist.  (Perfect consensus) (1–8 = 0 votes, 9 = 100% of 
votes) 
 General Recommendations 
 While information on the vaccination of patients with 
chronic lung diseases is summarized in the ACIP recom-
mendations on the CDC Web page  [82] , we decided to 
vote on the following topics.
 Pulmonary Rehabilitation and Long-Term Oxygen 
Therapy 
 IPF patients benefit from pulmonary rehabilitation, 
which has been shown to improve quality of life and ex-
ercise capacity  [83] . Exercise capacity and fatigue can pre-
dict general physical activity in patients with IPF  [84] .
 Although few studies are available, a retrospective 
analysis suggested benefits from oxygen supplementation 
for exercise performance in IPF patients  [85] .
 We recommend prescribing pulmonary rehabilitation to pa-
tients with IPF. We also recommend prescribing oxygen therapy 
during exercise if hypoxemia limits the exercise capacity, and 
home oxygen therapy if Pa O 2 reaches the standard threshold of 
55 mm Hg (7.33 kPa), or of 60 mm Hg (8 kPa) in case of polyglo-
bulia or right-sided heart insufficiency.  (Perfect consensus) (1–
 8 = 0 votes, 9 = 100% of votes) 
 Mechanical Ventilation 
 Acute respiratory failure may be treated by high-flow 
nasal oxygen, noninvasive ventilation, or invasive me-
chanical ventilation. Few data are available on the role of 
high-flow nasal oxygen in IPF  [86] . Invasive mechanical 
ventilation has been consistently associated with a very 
high mortality among IPF patients in the ICU setting 
(>90%)  [87] . However, in a recent, large, nationwide co-
hort analysis in the USA, in-hospital mortality among pa-
tients with IPF requiring invasive mechanical ventilation 
was approximately 50%  [88] . This trend may also be due 
to contemporary management approaches to acute lung 
injury (lung-protective ventilation strategies). Noninva-
sive ventilation can be used in case of acute exacerbation 
and respiratory failure (hypercapnia) in selected patients 
with hypoxemic respiratory failure in order to try to pre-
vent endotracheal intubation. Acceptance and setting of 
noninvasive ventilation might be difficult to achieve in 
IPF patients with altered lung mechanics, and the out-
come of patients failing noninvasive ventilation is poor 
 [89, 90] .
 For patients with IPF and acute respiratory failure, we suggest 
to use invasive mechanical ventilation if a reversible cause such 
as an infection, pulmonary embolism, heart failure, or other is 
present. In acute exacerbation of IPF, which is associated with a 
poor prognosis, the benefit from invasive ventilation is less clear 
and should be discussed on a case-by-case basis. Noninvasive 
ventilation can be used. If invasive mechanical ventilation is re-
quired for elective surgery, the ventilation strategy should be 
planned in advance and should aim at reducing the risk of trig-
gering an acute exacerbation.  (Very good consensus) (1–6 = 0 
votes, 7 = 10% of votes, 8 = 0 votes, 9 = 90% of votes) 
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 Palliation 
 In general, advanced care planning and palliative care 
are still neglected for IPF patients. Many IPF patients die 
in a hospital setting with late referral for palliation  [91] . 
Underuse of palliative care has been reported for patients 
with IPF  [92] . Palliative care should be discussed early in 
the course of IPF with patients who are ineligible for lung 
transplantation or with a poor lung function or perfor-
mance status. Patients’ values, goals, and therapeutic 
preferences should be taken into account. A decision to 
stop IPF-specific therapy should be based on individual 
patient assessment.
 We recommend introducing palliative care on an individual 
case basis. Patients with severe IPF may choose not to be treated 
with antifibrotic drugs. This should be discussed with these pa-
tients and be respected. Nevertheless, pharmaceutical and non-
pharmaceutical treatment options should be proposed to all pa-
tients.  (Very good consensus) (1–3 = 0 votes, 4 = 20% of votes, 
5–8 = 0 votes, 9 = 80% of votes) 
 Selected Comorbidities and Complications:
Acute Exacerbation and PH 
 How Should Acute Exacerbation of IPF Be Treated? 
 Secondary causes of respiratory failure should be 
searched for, since they might influence prognosis and ther-
apy  [25] . In patients with severe respiratory impairment, 
exclusion of infection by invasive procedures such as BAL 
is often difficult; therefore, empirical antibiotic treatment is 
often used  [93] . In addition, antiviral treatment can be in-
dicated according to the clinical circumstances  [94] . Intra-
venous corticosteroids as early as possible are the recom-
mended treatment, but evidence on their efficacy is lacking 
 [1] . The benefit from initiating pirfenidone or nintedanib 
treatment during acute exacerbation is unknown.
 We suggest not starting pirfenidone or nintedanib treatment 
at the time of acute exacerbation for patients with IPF requiring 
hospital admission, but previous treatment might be continued. 
As a practical approach, we suggest that antibiotic treatment 
should be administered if an infection cannot be excluded with 
certainty. The role of corticosteroids remains unclear. A short 
course of steroids (i.e., administration of intravenous methyl-
prednisolone for a few days) may be considered in some cases. 
However, evidence on the efficacy of this treatment is lacking. 
 (Very good consensus) (1–3 = 0 votes, 4 = 10% of votes, 5–6 = 
0 votes, 7 = 10% of votes, 9 = 80% of votes) 
 Should PH Be Treated in IPF Patients? 
 PH occurs in IPF patients  [43] . In patients with mild-
to-moderate restriction due to IPF, PH was found in 24% 
of the cases  [95] . In patients with mild ILD but severe PH, 
it may be difficult to determine whether PH is secondary 
to lung disease or if the patients have pulmonary arterial 
hypertension in addition to a chronic lung disease. Cur-
rent guidelines do not recommend treatment of PH in 
IPF  [45] . In addition, a recent study on riociguat in PH 
due to idiopathic ILD had to be prematurely stopped
because of increased mortality  [96] . Because of the poor 
prognosis, specific PH therapy for IPF patients with a 
mean pulmonary artery pressure  ≥ 35 mm Hg should be 
evaluated at a center with expertise in PH where there is 
also expertise in ILD for individualized patient care  [45] . 
A recent review on behalf of the Swiss Society for Pulmo-
nary Hypertension summarizes the challenges posed by 
PH in chronic lung diseases including ILD  [97] .
 We recommend that specific treatment of PH in IPF should 
not be introduced if PH can be reasonably attributed to IPF, i.e., 
if it corresponds to group 3.2 of the international PH classifica-
tion. If PH is suspected to occur independently of IPF, a specific 
evaluation should be done at a center with expertise in PH and 
ILD.  (Very good consensus) (1–8 = 0 votes, 8 = 10% of 
votes, 9 = 90% of votes) 
 Should Gastroesophageal Reflux Be Treated in IPF? 
 Acid gastroesophageal reflux is considered to contrib-
ute to epithelial cell injury and thus to the pathogenesis 
of IPF. Whether  Helicobacter pylori is involved in the 
pathogenesis of IPF remains unclear, since a recent study 
could not show its presence in lung biopsies  [98] . Never-
theless, gastroesophageal reflux is considerably prevalent 
in patients with IPF. Anti-reflux treatment, however, has 
been controversially discussed  [99] . One prospective ob-
servational study showed reduced disease progression re-
garding FVC and exacerbations  [100] , while a new post 
hoc evaluation of clinical studies on IPF shows increased 
numbers of overall and pulmonary infections in advanced 
IPF patients treated with antacids compared to those not 
treated with antacids  [101] . Furthermore, patients with 
antacid treatment at baseline receiving nintedanib seemed 
to do worse than those without antacid treatment  [99] . 
Promising surgical interventions to inhibit acid as well as 
anti-acid reflux with Nissen fundoplication in IPF are 
currently studied in an ongoing clinical trial (WRAP-
IPF)  [99] . Current international guidelines recommend 
conditional treatment with proton pump inhibitors re-
gardless of patients’ gastroesophageal reflux status  [2] , 
which is controversially discussed  [99] .
 We recommend treating symptomatic reflux in IPF patients, 
but not asymptomatic reflux, since evidence is missing.  (Very 
good consensus) (1–5 = 0 votes, 6 = 10% of votes, 7 = 10% of 
votes, 8 = 10% of votes, 9 = 70% of votes) 
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 How Should Cough and Dyspnea Be Treated 
Symptomatically in IPF? 
 Chronic cough and dyspnea are the main symptoms 
presented by IPF patients  [1] . Unfortunately, current an-
tifibrotic treatments have not been shown to improve 
these symptoms. Current antitussive medications have 
only limited benefit, and thalidomide has been shown to 
reduce cough but has not been routinely used due to pos-
sible toxicities  [53] . In Switzerland, some patients im-
proved under azithromycin treatment, possibly due to 
immunomodulatory mechanisms. This treatment is in-
vestigated in a placebo-controlled trial in Switzerland that 
is currently recruiting  [102] .
 We suggest that chronic cough and dyspnea are empirically 
treated with currently available antitussive drugs, as well as with 
opioids for advanced dyspnea in palliative situations. For chron-
ic cough, inducing factors need to be searched for and treated 
accordingly. These include reflux and obstructive sleep apnea 
syndrome, which are common comorbidities in IPF.  (Very good 
consensus) (1–6 = 0 votes, 7 = 10% of votes, 8 = 20% of votes, 
9 = 70% of votes) 
 Conclusion 
 Accurate diagnosis of ILDs is more important than 
ever, since treatment of IPF substantially differs from that 
of other ILDs. Evidence suggests that formal MDD among 
experts in the field of ILD improves the accuracy of IPF 
diagnoses. Whenever possible, patients should be referred 
to an ILD reference center for diagnosis and treatment ini-
tiation. Patients should be registered in national registries 
of cohort studies to monitor treatment effects and compli-
cations on a large scale in Switzerland. Off-label use and 
combination therapies should only be considered in a clin-
ical study setting at this time. The choice of treatment cur-
rently depends on various parameters including patients’ 
preferences and individual tolerance to side effects.
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